Tessera Therapeutics IPO

Tessera Therapeutics is pioneering Gene Writing technology, a next-generation approach to genetic medicine that can write therapeutic messages into the genome without causing double-strand DNA breaks. Unlike traditional CRISPR systems that cut DNA, Tessera's platform inserts, deletes, or replaces genes through a process called mobile genetic element-mediated Gene Writing, potentially offering safer and more precise genetic modifications.

The company's technology platform is designed to address genetic diseases that have been difficult to treat with existing gene editing approaches, including conditions requiring large gene insertions or corrections. Tessera is developing treatments for inherited diseases affecting the liver, eye, muscle, and central nervous system, with a focus on creating durable, one-time genetic medicines that could provide lifelong therapeutic benefit.